NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has entered into securities purchase agreements with investors to sell 1.5 million units at a price of $4.00 per unit, with each unit consisting of one share of Series A Senior Convertible Preferred Stock (“the Preferred Stock”) initially convertible into one share of common stock and one warrant to purchase one share of common stock, expected to yield gross proceeds to the Company of $6 million, before deducting offering-related expenses.

纽约--（商业新闻短讯）--临床阶段癌症免疫治疗和抗体药物结合生物技术公司OS Therapes，Inc.（纽约证券交易所代码：OSTX）（“OS Therapes”或“the Company”）今天宣布，它已与投资者签订证券购买协议，以每单位4美元的价格出售150万单位，每个单位由一股A系列高级可转换优先股（“优先股”）组成，最初可转换为一股普通股和一份购买一股普通股的认股权证，预计在扣除发行相关费用之前，公司将获得600万美元的总收益。

The conversion price of the Preferred Stock into shares of common stock is $4.00 and the exercise price of the warrants is $4.40 per share. The private placement is expected to close on or about December 27, 2024, subject to the satisfaction of customary closing conditions..

优先股转换为普通股的价格为4.00美元，认股权证的行权价格为每股4.40美元。预计私募将于2024年12月27日左右结束，但须满足常规结束条件。。

The Company intends to use the proceeds from the private placement for working capital, primarily focused on the clinical and regulatory milestones to support commercialization of the Company’s lead therapeutic candidate OST-HER2 in the treatment of recurrent, resected metastatic osteosarcoma in the United States in 2025, and for general corporate purposes.

该公司打算将私募收益用作营运资金，主要集中在临床和监管里程碑上，以支持该公司的主要治疗候选OST-HER2在2025年美国治疗复发性切除转移性骨肉瘤方面的商业化，并用于一般公司目的。

The FDA has granted OST-HER2 rare pediatric disease, fast track and orphan drug designations..

FDA已授予OST-HER2罕见儿科疾病、快速通道和孤儿药名称。。

Brookline Capital Markets, a division of Arcadia Securities, LLC, served as placement agent and Ceros Financial Services, Inc. was engaged as a selected dealer to the placement agent.

Brookline Capital Markets是Arcadia Securities，LLC的一个部门，担任配售代理，Ceros Financial Services，Inc.被聘为配售代理的选定经销商。

The securities being issued and sold in the private placement, as well as the common shares the securities are convertible or exercisable into, have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.

私募发行和出售的证券以及证券可转换或可行使的普通股尚未根据1933年修订的《证券法》（“证券法”）或任何州证券法进行登记，并且不得在美国发售或出售，除非根据有效的登记声明或《证券法》登记要求的适用豁免。

The Company has agreed to file a registration statement with the Securities and Exchange Commission (the SEC”) registering the resale of the shares of common stock issued in this private placement (the “Resale Shares”)..

公司已同意向美国证券交易委员会（SEC）提交一份登记声明，登记本次私募发行的普通股股份（“转售股份”）的转售情况。。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售要约或招揽购买要约，也不构成在任何州或其他司法管辖区出售证券的行为，在任何州或其他司法管辖区的证券法律规定的注册或资格之前，该等要约、招揽或出售将是非法的。

Any offering of the Resale Shares under the resale registration statement will only be by means of a prospectus..

转售登记声明项下的任何转售股份发售只能通过招股说明书的方式进行。。

For more information, please see the Company's website at www.ostherapies.com.

有关更多信息，请访问该公司的网站www.ostherapies.com。

About OS Therapies

关于操作系统疗法

OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein.

OS Therapes是一家临床阶段肿瘤公司，专注于骨肉瘤（OS）和其他实体瘤治疗的鉴定，开发和商业化。该公司的主要资产OST-HER2是一种免疫疗法，利用李斯特菌的免疫刺激作用，启动针对HER2蛋白的强烈免疫反应。

The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer.

该公司已经完成了41名患者的OST-HER2在切除的复发性骨肉瘤中的2b期临床试验的登记，预计将于2024年第四季度取得结果。OST-HER2除了在各种乳腺癌模型中显示出强大的临床前疗效数据外，还完成了主要针对乳腺癌患者的1期临床研究。

OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates.

OST-HER2已被美国农业部有条件批准用于治疗患有骨肉瘤的犬科动物。此外，OS Therapes正在推进其下一代抗体-药物偶联物（ADC）平台，称为可调ADC（tADC），其特征在于可调的定制抗体接头有效载荷候选物。

This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com..

该平台利用该公司专有的硅胶接头技术，可以为每个接头提供多个有效载荷。有关更多信息，请访问www.ostherapies.com。。

Forward-Looking Statements

前瞻性声明

This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts included in this press release, including, but not limited to, OS Therapies’ expectations regarding the completion of the private placement, the satisfaction of customary closing conditions related to the private placement and the expected receipt and intended uses of the proceeds from the private placement, are forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》定义的“前瞻性声明”。除本新闻稿中包含的历史事实声明外，所有声明均为前瞻性声明，包括但不限于OS Therapes对完成私募、满足与私募相关的惯例交割条件以及预期收到和预期使用私募收益的预期。

OS Therapies cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, uncertainties related to market conditions and the completion of the private placement on the anticipated terms or at all; the expected future balances of the Company’s cash, cash equivalents and short-term investments; the expected duration over which the Company’s cash, cash equivalents and short-term investments balances will fund its operations; and other risks and uncertainties described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q.

OS Therapes提醒读者，截至本新闻发布之日，前瞻性陈述是基于管理层的预期和假设，并受到某些风险和不确定性的影响，这些风险和不确定性可能导致实际结果产生重大差异，包括但不限于与市场状况相关的不确定性以及私募是否按预期条款完成或根本不完成；公司现金、现金等价物和短期投资的预期未来余额；公司现金、现金等价物和短期投资余额为其运营提供资金的预期期限；以及公司于2024年11月12日提交给证券交易委员会（“SEC”）的表s-1登记声明中“风险因素”和“管理层对财务状况和经营成果的讨论和分析”中描述的其他风险和不确定性，以及我们于2024年11月27日修订的其他后续文件，包括但不限于我们在表10-Q中提交的季度报告。

Forward-looking statements reflect our analysis only on their stated date, and OS Therapies takes no obligation to update or revise these statements except as may be required by law..

前瞻性声明仅在声明日期反映我们的分析，OS Therapes没有义务更新或修订这些声明，除非法律可能要求。。